Allogene Therapeutics, Inc.·4

Feb 5, 4:15 PM ET

Parker Geoffrey M. 4

4 · Allogene Therapeutics, Inc. · Filed Feb 5, 2025

Insider Transaction Report

Form 4
Period: 2025-02-03
Parker Geoffrey M.
CHIEF FINANCIAL OFFICER
Transactions
  • Sale

    Common Stock

    2025-02-03$1.73/sh4,361$7,5451,301,540 total
Footnotes (1)
  • [F1]Represents the number of shares sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plant to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

Documents

1 file
  • 4
    wk-form4_1738790139.xmlPrimary

    FORM 4